Myeloma Information Specialist

Update on support services available from Myeloma UK 

All myeloma patients have been advised to shield for 12 weeks to protect themselves from COVID-19. At Myeloma UK, we recognise this may cause psychological and emotional stress for many patients and their families and those with related conditions.   Our Myeloma Infoline (0800 980 3332, UK or 1800 937 773, Ireland) and Ask the Nurse…

Man watching webinar

Myeloma and COVID-19 virtual educational resources for healthcare professionals 

During the COVID-19 pandemic, healthcare professionals looking after myeloma patients face important and difficult decisions about the best way to treat their patients, whilst minimising their risk of infection. Several myeloma specialists have been sharing their experience as they work together to consider the safest and most effective ways to manage this vulnerable group of patients. Here we have compiled a short list of informative webinars, podcasts and articles to keep…


Myeloma UK creates COVID-19 Information Hub 

Myeloma UK have developed an information hub to help keep patients up to date with the latest news on COVID-19. The COVID-19 Information Hub is a one stop shop for information about the COVID-19 pandemic and how it is affecting patients’ treatment and care. The Hub is being regularly updated with the latest news and guidance from the UK Government…

Sarah and Ira and ASH 2019

Highlights from the American Society of Haematology 2019

The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…

ASH 2019

Myeloma UK funded research presented at ASH 2019

  The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. Our Director of Research Sarah McDonald and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic attended to learn about the latest myeloma research and see the progress from Myeloma UK funded research. Results from research part-funded by Myeloma UK, the…

Review of drug approval

Update on NICE review of drug approval methods

The way evidence is used to approve new treatments for use on the NHS is set to change, under a review being carried out by the National Institute for Health and Care Excellence (NICE). The review of methods, running throughout 2020, is an opportunity to address some of the challenges in approving treatments: for example, ensuring…